MOUNT TAM BIOTECHNOLOGIES, INC. (OTCMKTS:MNTM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0
MOUNT TAM BIOTECHNOLOGIES, INC. (OTCMKTS:MNTM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

MOUNT TAM BIOTECHNOLOGIES, INC. (OTCMKTS:MNTM) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 20, 2018, Timothy Powers, the Chief Scientific Officer (“CSO”) and a member of the Board of Directors of Mount Tam Biotechnologies, Inc., a Nevada corporation (the “Company”), informed the Company of his intention to immediately resign from his positions (i) as CSO and (ii) as a member of the Board of Directors. Mr.Powers did not advise the Company of any disagreement with the Company on any matter relating to its operations, policies or practices that resulted in his resignation. By agreement of the Company and Mr. Powers, Mr. Powers’ resignation as CSO was made effective September 5, 2018. Effective upon Mr. Powers’ resignation as a director, the size of the Company’s Board of Directors was reduced from five to four directors.

About MOUNT TAM BIOTECHNOLOGIES, INC. (OTCMKTS:MNTM)

Mount Tam Biotechnologies, Inc., formerly TabacaleraYsidron, Inc., is a specialty biopharmaceutical company established to develop and bring to market a portfolio of pharmaceutical products targeting the treatment of autoimmune diseases. The Company is focused on the development of product candidate in the field of systemic lupus erythematosus (SLE), an orphan autoimmune disease. The Company’s product candidate, TAM-01, is a rapamycin analog, which exerts its action through direct binding and inhibition of the mammalian Target of Rapamycin (mTOR). mTOR is a key regulatory pathway, which is altered in individuals suffering from autoimmune disorders, including lupus. The Company’s product candidate, TAM-01, is a small-molecule inhibitor of mTOR. TAM-01 has completed preliminary toxicology, safety, pharmacokinetics (PK), absorption, distribution, metabolism and excretion (ADME), and preliminary scale up manufacturing studies.